Rebecca S Kristeleit

Early oncology clinical trial design in the era of molecular-targeted agents.

Johann S de Bono, J. D. de Bono, R. Kristeleit, 2010, Future oncology.

Homologous recombination deficiency and ovarian cancer.

Y. Drew, J. Ledermann, R. Kristeleit, 2016, European journal of cancer.

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Anne Floquet, Andrew R Allen, James X. Sun, 2017, The Lancet. Oncology.